The TB Alliance and AstraZeneca announced today at the 2010 BIO International Convention that they have entered into a research collaboration agreement to accelerate the discovery, development and clinical use of drugs against tuberculosis (TB), including drug-resistant strains of the disease. One in five patients with TB are resistant to at least one of today’s standard first-line TB drugs according to the World Health Organization.